Zdrowie i gospodarka · 30/07/2008
FDA Releases Draft Guidance for Industry on Reducing Parvovirus B19 Risk in Plasma-Derived Products
The FDA has made available a draft document outlining recommendations for manufacturers of plasma-derived products to perform nucleic acid testing to reduce the risk of parvovirus B19 transmission, with the goal of preventing the use of contaminated plasma units.